Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man
- 79 Downloads
We have measured the metabolites (demethylated and hydroxylated) of amitriptyline in a group of seven normal volunteers. They were phenotyped as extensive or poor metabolizers using debrisoquine and bufuralol. The results demonstrate that the oxidative metabolism (aliphatic hydroxylation) of amitriptyline is under the same genetic control as that of debrisoquine and bufuralol.
However, phenotypic polymorphism cannot be used to predict amitriptyline blood concentration after a single oral dose, since the principal metabolic pathway of amitriptyline is demethylation and not aliphatic hydroxylation.
Key wordsAmitriptyline Nortriptyline Hydroxylated metabolites Oxidation polymorphism Hydroxylation polymorphism Pharmacogenetics Interindividual differences Pharmacokinetics
Unable to display preview. Download preview PDF.
- Balant L, Mc Ainsh J (1980) Use of metabolite data in the evaluation of pharmacokinetics and drug action. In: Jenner P, Testa P (eds) Concepts in drug metabolism. Marcel Dekker, New York, pp 311–371Google Scholar
- Baldessarini R (1980) Drugs and the treatment of psychiatric disorders. In: Goodman Gilman A, Goodman L, Gilman A (eds) The pharmacological basis of therapeutics, 6th edn. Mcmillan, New York, pp 391–447Google Scholar
- Dayer P, Courvoisier F, Balant L, Fabre J (1982a) Beta-blockers and drug oxidation status. Lancet I:509Google Scholar
- Dayer P, Balant L, Courvoisier F, Küpfer A, Kubli A, Gorgia A, Fabre J (1982b) The genetic control of bufuralol in man. Eur J Drug Metab Pharmacokin 7:33–77Google Scholar
- Eichelbaum M (1982) Defective oxidation of drugs: Pharmacokinetic and therapeutic implications. Clin Pharmacokin 7:1–22Google Scholar
- Nebert DW (1981) Possible clinical importance of genetic differences in drug metabolism. Br Med J 283:537–542Google Scholar
- Pang KS, Rowland M (1978) Hepatic clearance of drugs. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokin Biopharmacol 5:625–633CrossRefGoogle Scholar
- Rowland M, Tozer TN (1980) Clinical Pharmacokinetics: Concepts and applications. Lea and Febiger, Philadelphia, p 331Google Scholar